Why GeneDx Holdings Corp.’s (WGS) Stock Is Down 5.24%
As of Friday, October 16, GeneDx Holdings Corp.’s WGS share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. WGS
$66.29
2.68
4.21%
October 19, 2026 4:00:00 PM
EST
Volume: 503,621
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Commentary & Analysis
Why GeneDx Holdings Corp.’s (WGS) Stock Is Down 6.41%
As of Tuesday, October 06, GeneDx Holdings Corp.’s WGS share price has dipped by 6.41%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why GeneDx Holdings Corp.’s (WGS) Stock Is Down 6.60%
As of Tuesday, September 29, GeneDx Holdings Corp.’s WGS share price has dipped by 6.60%, which has investors questioning if this is right time to buy.Michael Rose
Why GeneDx Holdings Corp.’s (WGS) Stock Is Up 6.08%
As of Thursday, September 24, GeneDx Holdings Corp.’s WGS share price has surged by 6.08%, which has investors questioning if this is right time to sell.Jenna Brashear
Why GeneDx Holdings Corp.’s (WGS) Stock Is Down 7.81%
As of Tuesday, September 22, GeneDx Holdings Corp.’s WGS share price has dipped by 7.81%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | WGS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,897.3 | $1,701.5 | 54% |
|
| Shares Out (Mil) | 29.7 | 81.4 | 37% |
|
| Institutional Ownership | 97.8% | 86.9% | 75% |
|
| Float (Mil) | 20.4 | 56.2 | 29% |
|
| Beta | 2.01 | 0.78 | 92% |
|
| Avg Daily Volume (000s) | 689 | 571 | 63% |
|
| Price Change (52-week) |
(45.6%) | 77.8% | 22% |
|
| Growth | WGS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 19.0% | 10.6% | 80% |
|
| Net Income (5yr) | 38.6% | (0.7%) | 90% |
|
| EPS (5yr) | na | 1.2% | na |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (17.3%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | $0.073 | $0.131 | $1.199 | |
| Month Ago EPS | $0.073 | $0.128 | $1.169 | |
| # Rev Up | 2 | 1 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $0.103 | ($0.064) | $1.104 | |
| Year/Year Chg | (112.2%) | (117.8%) | (342.5%) | |
| Financials | WGS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $454 | $1,505 | 40% |
|
| Net Income (TTM) (Mil) | ($106) | $26 | 11% |
|
| EPS (TTM) | ($3.640) | $0.200 | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($49) | $165 | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $2 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $162 | $394 | 48% |
|
| Enterprise Value (Q1) (Mil) | $2,952 | $2,284 | 54% |
|
| Valuation | WGS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.77 | 2.92 | 88% |
|
| P/E | na | 26.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | WGS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.4% | 27.0% | 80% |
|
| Net Margin | (23.4%) | 1.2% | 16% |
|
| ROA | (22.5%) | 2.1% | 19% |
|
| ROE | (40.8%) | 6.9% | 17% |
|
| Liabilities to Assets | 49.3% | 61.3% | 41% |
|
| F-Score | 4 | 5 | na |
|
Passing Stock Screens
As of 10/16/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.3% |
| +/- S&P 500: | +13.8 |
